Abstract: The purpose of this articles is to determine whether the cytochrome P450 2E1 (CYP2E1) Rsa I/Pst I gene polymorphism is correlated with respiratory system cancers.
INTRODUCTION
R espiratory system cancer, including lung cancer, laryngeal cancer, nasopharyngeal cancer, bronchus cancer, and cancers of other respiratory organs, is the most common malignant tumors that threaten the health of human worldwide.
1,2 Lung cancer was the most commonly diagnosed cancer as well as the leading cause of cancer death in males and was the leading cancer types for the estimated deaths in 2014. 1, 3 Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southern Asia and Northern Africa; the incidence reaches 25 per 100,000 people that is only 0.5-2 per 100,000 people in Europe and America. 4 With regard to laryngeal cancer, among the most common forms of cancers are the cancers of the upper respiratory tract. 3, 5 Despite recent advances in the therapy, the survival rate of laryngeal cancer remains low. 6 More and more researches have generally indicated that respiratory system carcinogenesis is a multifactorial, complex, and multistep event, in which several risk factors, such as the environmental factors, life habits, genes, and gene polymorphisms may play an important role in the development and progression of respiratory system cancers. [7] [8] [9] [10] [11] [12] However, the exact mechanism of cancer developments remains uncertain. Recently, many researches have been performed focusing on the relationship between gene polymorphism and susceptibility to respiratory system cancers. 9, 10, [13] [14] [15] Many research dedicated that cytochrome P450 (CYP) superfamily catalyzed enzymes for carcinogens. CYP enzymes were involved in the initiation of various cancers by activating several environmental pollutants to form DNA adducts. 16, 17 CYP 2E1, ethanol-inducible enzyme, a member of the CYP superfamily, is involved in the metabolic activation of many low-molecular-weight compounds, such as N-nitrosamines, aniline, vinyl chloride, and urethane. 18, 19 Molecular biological evidence showed that CYP2E1 Rsa I/Pst I polymorphism [À1239G>C (rs3813867) and À999C>T (rs2031920)] in the promoter of CYP2E1 enhanced the transcriptional activity of gene by altering its binding to transcription factor, that is, hepatocyte nuclear factor-1, 20 and influenced the susceptibility to N-nitrosamine-linked carcinogenesis, 21 indicating that genetic polymorphism of the Rsa I/Pst I gene might be associated with increased risk for cancers; therefore, many researches were performed to determine whether the Rsa I/Pst I polymorphism is associated with respiratory system cancers. Recently, in several studies, significant association has been found between CYP2E1 Rsa I/Pst I polymorphism and respiratory system cancer. For instance, the study by Su et al 22 suggested that CYP2E1 Rsa I/Pst I polymorphism reduced the risk of lung cancer; however, Hildesheim et al 23 thought that the presence of the high-producer C2 allele of CYP2E1 Rsa I/Pst I was correlated with an increased risk of NPC in the Taiwan population. The study by Tai et al 24 showed no statistically significant increased risk of laryngeal cancer among individuals that carried the C2 allele of CYP2E1 Rsa I/Pst I gene. Furthermore, no consolidated report has been conducted to investigate the association between CYP2E1 Rsa I/Pst I polymorphism and respiratory system cancers. Therefore, we performed the meta-analysis to make contribution to obtain a more exact evaluation of the association between CYP2E1Rsa I/Pst I polymorphism and respiratory system cancer risk.
MATERIALS AND METHODS

Search Strategy
We performed a literature research for all relevant articles studying association between the CYP2E1Rsa I/Pst I polymorphism and respiratory system cancers on PubMed, EMBASE, Cochrane Library Databases, China National Knowledge Infrastructure, and Wanfang Database (up to July 20, 2014), using the following searching terms: ''cytochrome p450 2E1 OR cytochrome p450 IIE1 OR CYP2E1 OR CYP2E1'' AND ''SNP OR polymorphism OR allele OR variation'' AND '''cancer OR carcinoma OR adenocarcinoma OR tumour OR tumor.'' There was no restriction on language; later, these articles were selected by reviewers to find out studies focusing on respiratory system cancers. The combined phrases and a hand search of references of original studies are also quoted on this topic.
Inclusion and Exclusion Criteria
Any study that was included was to meet the following criteria: evaluating the association between CYP2E1Rsa I/Pst I polymorphism and respiratory cancer risk; case-control studies; and sufficient data (allele and gene types frequency). Excluded criteria were: not case-control studies, such as reviews, comments, or case reports; and no sufficient data.
Data Extraction
Data extraction was carried out independently by 2 reviewers according to the predetermined criteria. Every discrepancy was settled through discussions till consensus was reached. Information extracted from each eligible study was extracted as follows: first author's name, year of publication, ethnicity of the study population, characteristics of cancer cases, source of controls, number of cases and controls, and number of different genotypes in cases and controls.
Data Synthesis and Statistical Analysis
Odds ratio (OR) with 95% confidence interval (CI) were calculated to assess the strength of the association between the CYP2E1Rsa I/Pst I polymorphism and the Records identified through database searching (n = 333)
Additional records identified through other sources (n = 2)
Records after duplicates removed (n = 266)
Records screened (n = 126)
Records excluded Not suitable for our study (n = 140)
Full-text articles assessed for eligibility (n = 58)
Full-text articles excluded, with reasons No sufficient data (n = 68)
Studies included in systematic review and meta-analysis (n = 34) respiratory system cancers under 5 genetic models: the allele contrast (C2 vs C1), dominant (C1C2 þ C2C2 vs C1C1), recessive (C2C2 vs C1C2 þ C1C1), homozygous (C2C2 vs C1C1), and heterozygous (C1C2 vs C1C1) models. Meanwhile, stratified analyses were performed by ethnicity and the type of tumor. The statistical heterogeneity assumption was assessed by the I 2 statistics to quantify inconsistency, which represents the proportion of interstudy variability that can be due to heterogeneity other than to chance. An I 2 value of >50% was considered as a significant heterogeneity among studies; so the pooled OR estimate of each study was calculated by the random effect model, otherwise, the fixed effect model was used. Sensitivity analysis and publication bias were also evaluated in our study. All statistical analyses were carried out using STATA version 12.0 (STATA Corp, College Station, TX). P < 0.05 was considered statistically significant. This is a systemic review about literatures, therefore ethical approval was not necessary for our research.
RESULTS
Study Characteristics
A total of 332 articles were preliminarily reviewed, among which 34 studies 22-55 with 7028 cases and 9822 controls eventually met the eligibility criteria ( Figure 1 
Meta-Analysis Results
Overall, there was significant association between CYP2E1Rsa I/Pst I polymorphism and respiratory system cancers risk (C1C2 vs C1C1: OR ¼ 0.85, 95% CI ¼ 0.78-0.93, P < 0.001; C1C2/C2C2 vs C1C1: OR ¼ 0.87, 95% CI ¼ 0.81-0.94, P < 0.001; Figures 2 and 3 ).
Sensitive Analysis and Publication Bias
We performed a leave-one-out sensitivity analysis to estimate the sensitivity of our study. Any single study was omitted, while the overall statistical significance does not change, indicating that the results are stable. Therefore, we can conclude that our meta-analysis data is relatively stable and credible.
Funnel plot and Begg test were performed to estimate the publication bias of studies. The shapes of funnel plot seemed symmetrical, suggesting without publication bias (Figure 4 ). These results were further supported by analysis via Begg and Egger tests (P ¼ 0.262).
DISCUSSION
The etiology of respiratory system cancers was so complicated that several risk factors were involved in the progression of respiratory cancers. In recent years, more researches focus on the relationship between genetic susceptibility and respiratory system cancers, such as ERCC1, XRCC1, Nt590 P21, Cylin D1, and BSF2. 13, 15, [56] [57] [58] CYP2E1 Rsa I/Pst I polymorphism was assessed in different types of respiratory system cancers. For lung cancer, the research by Su et al, 22 which included 64 patients with lung cancer and 64 healthy controls of the same ethnic origin, proved that the carrier state of 1 copy of the C2 CYP2E1 gene decreased the risk of lung cancer, which corresponded to some other studies. 25 subjects with no evidence of respiratory disease or cancer in any organ, with a conclusion that genetic polymorphisms of CYP2E1 was not associated with the overall risk of lung cancer, which was consistent with others. 26, 31, [33] [34] [35] [38] [39] [40] 42, 43, 46, 48, 49 With regard to nasopharyngeal and laryngeal cancer, the results of the studies 23,24,50 -55 were also controversial. The casecontrol study by Tai et al 24 indicated that an increased risk was associated with the CYP1A1 462Val/Val genotype, but not with the CYP2E1 Rsa I/Pst I genotype in a Han Chinese population. The study by Hildesheim et al 23 suggested that the CYP2E1 gene detected by Rsa I digestion (C2 allele) was found to have an increased risk of NPC. Therefore, it was necessary to integrate all these studies to make a comprehensive assessment. Furthermore, to our knowledge, no comprehensive study has previously been conducted to address this issue. Because of these conflicting results, we conducted this meta-analysis to provide a comprehensive assessment of the associations between CYP2E1 Rsa I/Pst I polymorphism and respiratory cancer risk. In our meta-analysis, significant association was found between CYP2E1 Rsa I/Pst I polymorphism and respiratory cancer risk, indicating that the carriers of C2 allele might be a genetic protective factor for the susceptibility to respiratory cancer. When stratified by cancer type, our study indicated that CYP2E1 Rsa I/Pst I polymorphism led to an decreased incidence of lung cancer risk under the heterozygote model (OR ¼ 0.82, 95% CI ¼ 0.74-0.91, P < 0.001), dominant model (OR ¼ 0.83, 95% CI ¼ 0.76-0.90, P < 0.001), and allele contrast (OR ¼ 0.85, 95% CI ¼ 0.73-1.00, P ¼ 0.045), which was consistent with several studies we included, 25, 28, 32, 37, 41, 44, 47 but not with some other studies. 26, 27, [29] [30] [31] [33] [34] [35] [36] [38] [39] [40] 42, 43, 45, 46, 48, 49 Previous metaanalyses 25, 59 also drew the same conclusion. Furthermore, the genotypes of CYP2E1 Rsa I/Pst I polymorphism among the patients with lung cancer in the study by Wang et al 42 and Huang et al 46 did not follow HWE, which might make contribution to the reason for these significant differences. In addition, our study also suggested that CYP2E1Rsa I/Pst I C2/C2 polymorphism led to an increased incidence of NPC risk in homozygote model (OR ¼ 1.85, 95% CI ¼ 1.20-2.85, P ¼ 0.005) and recessive model (OR ¼ 1.89, 95% CI ¼ 1.23-2.89, P ¼ 0.003), which was consistent with the findings of Hildesheim et al. 23 Small sample size of the study by Kongruttanachok et a 51 and insufficient statistical power in the study by Guo et al 50 might explain the difference from our result. However, with regard to laryngeal cancer, no significant association with CYP2E1 Rsa I/Pst I polymorphism was found in our meta-analysis, and all of the studies 24,53-55 we included showed the same results. In the subgroup of ethnicity, significant association was found in Asian populations, while there was no significant association in Caucasian and mixed populations, indicating that ethnicity might be an important risk factor in the development and progression of respiratory cancer. Several factors may lead to this difference, including living environment, racial background, and life habits. Besides, the unclear interaction of identified and unidentified genes may also contribute to carcinogenesis in respiratory system.
However, similar to most researches, our meta-analysis has limitations that may affect the veracity of result. First, respiratory system cancers included several cancers, while the association between CYP2E1Rsa I/Pst I polymorphism and other respiratory system cancers, such as bronchus cancer, were not performed by researchers, and was not involved in our meta-analysis, which might lead to some biases in the final conclusion. Second, the studies we included and these raw data did not provide sufficient information about the interaction between CYP2E1Rsa I/Pst I polymorphism and other risk factors, such as other gene polymorphism, living habits, and other exposures. Without these considerations, we could not draw an exact conclusion. Last, some of our studies 42, 46 we included were not abided by HWE, which might also lead to some biases.
In summary, our meta-analysis indicated that CYP2E1Rsa I/Pst I polymorphism may be a protective factor for respiratory system cancer. Furthermore, significant association was also found in Asian populations. Considering the limitations listed above, larger well-designed studies are needed to further evaluate the associations of CYP2E1 Rsa I/Pst I polymorphism with the risk of respiratory system cancers.
